Clinical trial · no report yet · Phase 2
DG-03
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
- NCT04379596 ↗
- Active not recruiting
- AstraZeneca
- 78 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 37 | |
| Podcasts | 28 | |
| X threads | 13 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Gastric Cancer
- Interventions
- Fluorouracil (5-FU); Capecitabine; Durvalumab; Oxaliplatin; Trastuzumab; Trastuzumab deruxtecan; Cisplatin; Pembrolizumab; Volrustomig; Rilvegostomig
- Arms
- Arm 1A · Experimental
- Arm 1B · Experimental
- Arm 1C · Experimental
- Arm 1D(b) · Experimental
- Arm 1E(a) · Experimental
- Arm 1E(b) · Experimental
- Arm 2A · Active comparator
- Arm 2B · Experimental
- Arm 2C · Experimental
- Arm 2D · Experimental
- Arm 2E · Experimental
- Arm 2F · Experimental
- Arm 3A · Experimental
- Arm 3B · Experimental
- Arm 4A · Experimental
- Arm 4B · Experimental
- Part 5 Main Cohort · Experimental
- Part 5 Cohort 2 · Experimental
- Enrollment
- 452
- Primary outcomes
- Part 1: Occurrence of adverse events (AEs) and serious adverse events (SAEs), graded according to NCI CTCAE v5.0
- Part 1: Ocurrence of dose-limiting toxicities (DLTs)
- Part 1: Changes from baseline in laboratory parameters
- Part 1: Changes from baseline in vital signs
- Part 1: Changes from baseline in electrocardiogram (ECG) results
- Part 2, Part 3, Part 4 and Part 5: Endpoint assessed by Investigator per RECIST v1.1: Confirmed Objective Response Rate (ORR)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Jun 3, 2020
- Primary completion
- May 4, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04379596 · updated Aug 28, 2026
Publications
linked from the registry- Yu J, Mehta R. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma. J Natl Compr Canc Netw. 2025 May;23(5):e257036. doi: 10.6004/jnccn.2025.7036. PubMed 40341124